Insulin inhalation - MannKind Corporation

Drug Profile

Insulin inhalation - MannKind Corporation

Alternative Names: Afresa®; Afrezza; Insulin human - MannKind Corporation; Technosphere® Insulin

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MannKind Corporation
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2017 MannKind received a letter of fulfilment of post-marketing requirements for PMR 2166-2 and PMR 2166-3 from the US FDA for the treatment of Type-1 and Type-2 diabetes mellitus
  • 02 Oct 2017 Efficacy data from a phase I trial in Type-1 diabetes mellitus released by MannKind Corporation
  • 28 Sep 2017 Phase-II clinical trials in Type-1 diabetes mellitus (In adolescents, In children) in USA (Inhalation) (NCT02527265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top